Cannabis Law Report

MAY 10, 2022

First comprehensive study reveals why Australians take medicinal cannabis. First academic study of national medicinal cannabis data. The first in-depth study of Australia’s medicinal cannabis program, which began in 2016, shows the drug is being increasingly prescribed for various conditions. 11 May 2022.

Medicine 52

Medicine Clinical Trials Sleep Data 52

Cannabis Law Report

OCTOBER 6, 2021

Flora Pharma’s objective is to create and leverage a proprietary drug development platform in collaboration with an artificial intelligence and machine learning group to identify new bioactive compounds within the cannabis plant that interact with certain gene targets responsible for specific disease states and conditions.

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical Events 52

Cannabis Law Report

AUGUST 28, 2022

Cannabinoids are a class of chemical compounds found in the cannabis plant. There are over 100 cannabinoids, and they are responsible for the plant’s therapeutic effects. Cannabinoids interact with our body’s endocannabinoid system, which regulates many important functions, including mood, appetite, and pain.

Cannabinoids 52

Cannabinoids Trichome Treatment Clinical Trials 52

The Joint Blog

NOVEMBER 8, 2020

According to a new study published in the journal Pain Medicine and epublished by the National Institute of Health, the daily use of marijuana oil is effective and well-tolerated among patients with fibromyalgia. Interested in reading the study’s full abstract? mg/mL of THC and 0.51

Clinical Trials 49

Clinical Trials Oil Therapy Marijuana 49

Puff Puff Post

NOVEMBER 5, 2019

. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a Clinical Trial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinical trial for INM-755 in healthy volunteers. For more information, visit www.inmedpharma.com. About INM-755.

Clinical Trials 40

Clinical Trials Pharmaceutical Cannabinoids Data 40

Cannabis Law Report

SEPTEMBER 2, 2021

The use of cannabinoids in the treatment of medical conditions offers major opportunities and challenges to anyone operating in the space. In the US, sales of medical flower and vaporised products remain dominant amongst unapproved medicines, but there is also an increase in sales of pharmaceuticals, mainly Epidiolex®.

Pharmaceutical 105

Pharmaceutical Clinical Trials Research and Development Cannabinoids 105

Project CBD

FEBRUARY 27, 2023

For all modern medicine can do, many mysteries remain unsolved. Researchers have been investigating the use of cannabis to treat fibromyalgia’s constellation of symptoms for decades, with early clinical trials in the 2000s 1-4 suggesting a possible benefit of both pure THC and flower in managing the disease. What is long COVID?

THC 144

THC CBD Sleep Clinical Trials 144

Cannabis Law Report

MAY 10, 2022

More than half of all prescriptions for medicinal cannabis in Australia are written by doctors in Queensland, with prescriptions often given for conditions there is little evidence medicinal cannabis can treat, new research reveals. We are aware of clinical trials in that space, but not strong evidence.”.

Medicine 52

Medicine Clinical Trials Data Sleep 52

The Cannigma

FEBRUARY 1, 2023

Patients are often left to their own devices when looking into cannabis and cancer, given the lack of clinical evidence, and stigma surrounding the use of the plant as medicine. Individuals who use cannabis-based medications often want to cure their cancer, not just reduce the symptoms that come with the condition.

Clinical Trials 145

Clinical Trials Research and Development Therapy Cannabinoids 145

Project CBD

OCTOBER 26, 2023

There is a growing body of anecdotal and scientific evidence that the “major cannabinoids” tetrahydrocannabinol (THC) and cannabidiol (CBD), certain “minor cannabinoids” (some without a name), and other cannabis compounds have antineoplastic action against cancer cells. THC binds to two types of cannabinoid receptors, CB1 and CB2.

Research and Development 343

Research and Development Cannabinoids Terpenes Pharmaceutical 343

Puff Puff Post

MARCH 10, 2020

InMed and CHDR are currently preparing the Clinical Trial Application for a second Phase 1 clinical trial (755-102-HV), planned to begin in the second quarter of 2020, which will examine the local safety of INM-755 on small areas of wounded skin in healthy volunteers. For more information, visit www.inmedpharma.com.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Cannabinoids 40

MMJ Recs

APRIL 1, 2024

CBD, one of the many cannabinoids found in the cannabis plant, has been garnering attention for its promising effects on various health conditions. From its anti-inflammatory properties to its ability to alleviate pain, CBD shows promise in addressing various health conditions.

CBD 52

CBD Clinical Trials Chronic Pain Epilepsy 52

Cannabis Law Report

DECEMBER 21, 2021

According to certain promising animal studies, CBG may one day be regarded as beneficial for the medicinal uses indicated below. They concluded that CBG should be evaluated for clinical trials in individuals with IBD. There are, however, very few human studies done on this subject, and more research is needed in this area.

Conditions 52

Conditions Research and Development Clinical Trials Oil 52

Cannabis Law Report

NOVEMBER 12, 2021

Neil Mahapatra is a co-founder of the Oxford Cannabinoid Technologies (OCT) which floated on the LSE in the May this year, he is also founder of UK venture capital business Kingsley Capital Partners (KCP). Oxford Cannabinoid Technologies’ Shares Fall A Further 20% As Chairman Stands Down Following Market Rule Breach.

Cannabinoids 98

Cannabinoids Clinical Trials Research and Development Pharmaceutical 98

Veriheal

JULY 7, 2023

Thankfully, a team of scientists at Medicinal Genomics may have just stumbled upon a solution. Plants hit with HLVd show issues like yellow leaves, abnormal branching, stunted development, and nearly 50% loss in cannabinoid production. The new law covers the use of MDMA and psilocybin to treat certain conditions.

Legalization 96

Legalization Clinical Trials Research and Development History 96

Cannabis Law Report

OCTOBER 5, 2021

Systematic literature review of the therapeutic value, benefits and risks of MDMA and psilocybin for the treatment of mental health conditions. The Panel’s report will be considered by the Advisory Committee of Medicines Scheduling (ACMS) at the 3 November 2021 meeting. The review excludes pre-clinical trials (i.e.

Treatment 52

Treatment Conditions Medicine Clinical Trials 52

United Patients Group

JANUARY 8, 2023

In fact, cannabis has been used for thousands of years as a medicine. Cannabis has been shown to be an effective treatment for a variety of conditions caused by bacteria, viruses and fungi. This is because it contains cannabinoids, which have anti-inflammatory properties. Cannabis and the Immune System. We Need More Research.

Blood Pressure 108

Blood Pressure Sleep Cannabinoids Clinical Trials 108

FloridaMarijuana.net

AUGUST 15, 2018

Additionally, the ACPA reported on a clinical trial that suggests that inhaled cannabis may provide short-term relief from Neuropathy. The endocannabinoid system consists of cannabinoid receptors all over the body. These damaged nerve fibers send incorrect signals to other pain centers.

Chronic Pain 150

Chronic Pain Marijuana Patients Clinical Trials 150

Cannabis Law Report

DECEMBER 23, 2021

Research on the endocannabinoid system is one of the most promising avenues for new therapeutics in medicine at the moment. This report has been compiled to assist interested parties in understanding the market for the medical use of cannabinoids and where it may be heading. C3 Cannabinoid Compound Company. Companies Mentioned.

Pharmaceutical 96

Pharmaceutical Clinical Trials Research and Development Cannabinoids 96

LifeCannMD

FEBRUARY 27, 2024

How Medical Marijuana Is Changing Lives with Crohn’s Disease Medical Marijuana is a great treatment option for battling Crohn’s Disease, a chronic inflammatory bowel condition that affects millions worldwide. Fernando Fandino-Sende , Double Board Certified, Cardiologist & Internal Medicine Doctor in Miami, FL.

Marijuana 59

Marijuana Clinical Trials Treatment Therapy 59

Medicinal Marijuana Association

FEBRUARY 11, 2024

You may have heard whispers of cannabis being used to address a specific eye condition, but what does the research truly reveal about its effectiveness? Glaucoma: Understanding the Condition Understanding glaucoma is crucial for recognizing its symptoms and seeking timely treatment.

Treatment 52

Treatment Blood Pressure Conditions Clinical Trials 52

The Cannigma

FEBRUARY 2, 2021

Of these consumers, over half said the drug had a beneficial clinical effect on their condition. As medicinal cannabis treatments are now legal in many parts of the world, naturally, there is a growing interest in whether the products can treat neurological conditions like Parkinson’s disease.

Patients 87

Patients Clinical Trials Research and Development Treatment 87

Cannabis Law Report

NOVEMBER 24, 2019

Cannabis-based medicinal products. Making decisions using NICE guidelines explains how we use words to show the strength (or certainty) of our recommendations, and has information about prescribing medicines (including off-label use), professional guidelines, standards and laws (including on consent and mental capacity), and safeguarding.

Medicine 59

Medicine Chronic Pain Research and Development Treatment 59

FloridaMarijuana.net

JUNE 13, 2018

Additionally, the NCI recognizes that cannabinoids “may have benefits in the treatment of cancer-related side effects.”. Cannabinoids are extracted from the cannabis plant and an extract oil is created. It is important to speak with a medical marijuana physician to determine which method will work best with your medical condition.

Clinical Trials 189

Clinical Trials Marijuana Patients Chronic Pain 189

Cannabis Law Report

SEPTEMBER 22, 2021

Oxford Cannabinoid Technologies Holdings plc. . Access to Canopy Growth’s cannabinoid library including 335 derivatives and 14 patent families. Accelerated timelines to clinical trials and expansion of drug development pipeline. Phase 1 clinical trials are scheduled for Q3 2022 with Phase 2 trials expected in Q2 2023.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Cannabinoids 52

Veriheal

APRIL 11, 2022

The final goal is to introduce medicinal cannabis products to the pharmaceutical drug market. Groff North America is proud to be producing research-grade marijuana, so we can continue growing the field of cannabis-based medicine,” reads an official statement from the company’s website. This means that U.S. Absolutely.”

Pharmaceutical 104

Pharmaceutical Research and Development DEA Clinical Trials 104

The Cannigma

JANUARY 13, 2023

Migraines are a peculiarly painful condition. Scientists still don’t understand exactly why migraines happen, nor how to cure the condition – but perhaps cannabis can help. A primary headache, such as a migraine, is its own condition, and not caused by a separate condition.

Terpenes 132

Terpenes Strains THC Treatment 132

Cannabis Law Report

AUGUST 14, 2021

The deal signed in March had sought to progress an over-the-counter medicine with the TGA using Emyria’s EMD-003 program and Cann’s Gelpell technology. Cann Group (CAN) and Emyria (EMD) mutually agree to drop a deal for the proposed registration of a Schedule 3 cannabidiol (CBD) product.

CBD 105

CBD Clinical Trials Programs Food 105

Veriheal

JUNE 29, 2021

Plant medicines and concoctions made from them have been utilized throughout the history of cultures around the world. In the last 100 years, many of the plant therapies that were embraced in history were outlawed by governments around the world and replaced by lab-made synthetic drugs we label medicine.

Therapy 55

Therapy DEA Patients Clinical Trials 55

Veriheal

MAY 3, 2022

The outcomes and measures used throughout the trial included changes in CUD symptoms; anxiety and depressive symptoms; pain severity; and insomnia symptoms. Clinical Trial Sample Size. a necessary question to address as medical marijuana becomes more accessible. Daily Cannabis Use as a Disqualifier.

Research and Development 98

Research and Development Clinical Trials Consumption Patients 98

Cannabis Law Report

JULY 27, 2021

–(BUSINESS WIRE)– Realm of Caring (RoC) , a nonprofit dedicated to cannabinoid research, has appointed Nicolas Schlienz, Ph.D., Research opportunities such as the ORR expand the existing scientific knowledge base to better inform clinical decision making, and also dispels the stigma surrounding medicinal cannabis use.”.

Data 105

Data Epilepsy Research and Development Clinical Trials 105

FloridaMarijuana.net

AUGUST 9, 2018

The University of Maryland School of Medicine (UMSOM) published a paper detailing the inadequacies of current research. The endocannabinoid system consists of cannabinoid receptors all over the body. Cannabis offers significant therapeutic benefits for a wide range of medical conditions.

Marijuana 190

Marijuana Patients Clinical Trials Treatment 190

The Cannigma

APRIL 12, 2023

CBN has made headlines and claimed shelf space as the next best cannabinoid for sleep. While CBN is often marketed as “the sleep cannabinoid ,” the reality is more complicated. Sleep is not often the focus of clinical trials on cannabis; rather it is often a secondary outcome. Has CBN been proven to help with sleep?

Sleep 133

Sleep Data Tincture Research and Development 133

Cannabis Law Report

FEBRUARY 15, 2019

Mr Shanmugam said this just before a joint statement by the Home Affairs and Health ministries which set out the government’s position the use of pharmaceutical products containing cannabinoids. They said, “To date, there are no studies which have validated the claims of unprocessed or raw cannabis being able to treat medical conditions,”.

Medicine 45

Medicine Pharmaceutical Law Cannabinoids 45

Cannabis Law Report

NOVEMBER 12, 2021

Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance addiction, today announced financial results for the first quarter of its fiscal year ending June 30, 2022 and reported recent business highlights. and Arjun Chanmugam, M.D.,

Pharmaceutical 52

Pharmaceutical Clinical Trials Business Research and Development 52

Kind Meds (Cannabis Education Blog)

NOVEMBER 18, 2020

It seems like the medical research community remains largely divided on the issue, with some insisting that cannabis use contributes to mental health condition diagnoses while others suggesting that people with mental health conditions are inherently drawn to cannabis use.

Treatment 111

Treatment Conditions CBD Clinical Trials 111

The Cannigma

MARCH 18, 2021

If cannabis is intended to be used as a medicinal or CAIM (complementary and integrative medicine) treatment for PD, formal recommendations are needed to fill the current knowledge gap around cannabis type, dosage , and efficacy,” the researchers wrote. Asked why, 35.5%

Patients 138

Patients Clinical Trials Treatment Cannabis 138